MZMarvin Zelen

Marvin Zelen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marvin Zelen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Randomized clinical trials

    by Lu Zheng, Marvin Zelen


  • Open Access

    Chapter 11: A Stochastic Model for Predicting the Mortality of Breast Cancer

    by Sandra Lee, Marvin Zelen

    Consider a cohort of women, identified by year of birth, some of whom will eventually be diagnosed with breast cancer. A stochastic model is developed for predicting the U.S. breast cancer mortality that depends on advances in therapy and dissemination of mammographic screening. The predicted mortality can be compared with the same cohort having usual care with no screening program and absence of modern therapy, or a cohort in which only a proportion participate in a screening program and have modern therapy. The model envisions that a woman may be in four health states: i.e., 1) no disease or breast cancer that cannot be diagnosed (S0), 2) preclinical state (Sp), 3) clinical state (Sc), and 4) disease-specific death (Sd). The preclinical disease refers to breast cancer that is asymptomatic but that may be diagnosed with a special exam. The clinical state refers to symptomatic disease diagnosed under usual care. One of the basic assumptions of the model is that the disease is progressive; i.e., the transitions for the first three states are S0→Sp→Sc. The other basic assumption is that any reduction in mortality associated with earlier diagnosis is due to a stage shift in diagnosis; i.e., early diagnosis results in a larger proportion of earlier stage patients. The model is used to predict changes in female breast cancer mortality in the U.S. women for 1975–2000. The model is general and may predict mortality for other chronic diseases that satisfy the two basic assumptions.


  • Open Access

    RESPONSE: Re: Risks of Cancer and Families

    by Marvin Zelen

    Bermejo and Hemminki have reanalyzed their data in which a sibling is either a proband or a case and have concluded that stratification by family size does not influence the relative risks of the various cancers. Their letter also states, “It is true that large families contributed more case patients to the analysis than did small families.” This is to be expected due to length-biased sampling; i.e., families tend to be larger if an offspring in the family has cancer.

  • Open Access

    Risks of Cancer and Families

    by Marvin Zelen

    A cluster of cancers diagnosed in families raises concern about family risk and the need for counseling. Because family members share similar genes or may have experienced common environmental challenges, it would not be surprising to find clusters of cancers in families. The investigation by Bermejo and Hemminki ( 1 ) raises some provocative questions regarding a family member being diagnosed with cancer and other family members later being diagnosed with the same cancer. Bermejo and Hemminki used the Swedish Family Cancer Database to explore the pattern of familial risk after diagnosis of the first cancer in a family. The main theme in the analysis was to determine if the first cancer diagnosed in a family would motivate other family members to seek examinations for cancer. If true, this would most likely lead to increased diagnoses of other family members in the period shortly after the diagnosis of the first cancer and would artificially inflate the cancer risk. The authors refer to this bias as “surveillance bias.” The cancers that are investigated are breast, prostate, colorectal, cervix, lung, and invasive melanoma. The authors present data in which a parent is a proband and similar data in which a sibling is a proband.


  • Open Access

    Overdiagnosis in early detection programs

    by Ori Davidov, Marvin Zelen

    Overdiagnosis refers to the situation where a screening exam detects a disease that would have otherwise been undetected in a person's lifetime. The disease would have not have been diagnosed because the individual would have died of other causes prior to its clinical onset. Although the probability of overdiagnosis is an important quantity for understanding early detection programs it has not been rigorously studied. We analyze an idealized early detection program and derive the mathematical expression for the probability of overdiagnosis. The results are studied numerically for prostate cancer and applied to a variety of screening schedules. Our investigation indicates that the probability of overdiagnosis is remarkably high.


  • Open Access

    The theory of case-control studies for early detection programs

    by Ori Davidov, Marvin Zelen

    Although case‐control studies are widely used for evaluating the benefit of early detection programs, the theoretical basis underlying this application has not been well developed. In this paper the properties of chronic disease case‐control studies for evaluating early detection programs are investigated. An idealized case‐control study is analyzed and the theoretical expression for the odds ratio associated with the benefit of screening is derived. The odds ratio is related to the natural history of disease and the screening program. Our results indicate that case‐control studies result in odds ratios that are surprisingly close to unity and consequently have low power.


  • Open Access

    Experimental design issues for the early detection of disease: novel designs

    by Ping Hu, Marvin Zelen

    This paper investigates two experimental designs which have been used to evaluate the benefit of the early detection of breast cancer. They have some advantages over a classical design (the screening program versus usual medical care) in that subjects in a control group may benefit by participating in the study. We refer to the two experimental designs as the up‐front (UFD) and close‐out (COD) designs. The UFD consists of offering an initial exam to all participants. Then they can be randomized to a usual care group or a screening group receiving one or more special examinations. If the outcome of the initial examination is included in the analysis, then the study can answer the question of the benefit of an additional screening program after an initial examination. If the analysis excludes all the cases diagnosed at the initial examination, then the analysis evaluates the benefit of a screening program after elimination of the prevalent cases. These prevalent cases are most likely to be affected by length bias sampling and consequently will tend to have less aggressive disease and live longer. As a result, the UFD can answer two scientific questions. The COD consists of randomizing subjects to a usual care group and a screened group. However, the usual care group receives an examination which coincides at the time of the last exam in the study group. In this paper the power of these two designs have been evaluated. In both cases the power is severely reduced compared to the usual control group receiving no special exams. The power is a function of the sensitivity of the exam, the number and spacings of the exams given to the screened group as well as the sample size, disease incidence of the population and the survival distribution. The theoretical results on power are applied to the Canadian National Breast Cancer Study (ages 40–49) which used an UFD and the Stockholm Mammography Breast Cancer Screening Trial which utilized a COD.